Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-009-1027-4PMID 19484470
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).

  2007cited by this paper
• Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac.

  2007cited by this paper
• Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice

  2007influential reference
• The genetic and molecular pathogenesis of NF1 and NF2.

  2006cited by this paper
• Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells

  2006cited by this paper
• Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis

  2006cited by this paper
• The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.

  2005cited by this paper
• The Phosphorylation status of merlin is important for regulating the Ras-ERK pathway.

  2005cited by this paper
• Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells

  2005cited by this paper
• A Clue to the Therapy of Neurofibromatosis Type 2: NF2/Merlin Is a PAK1 Inhibitor

  2004cited by this paper
• Targeting RAS signalling pathways in cancer therapy

  2003cited by this paper
• The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Understanding Ras: 'it ain't over 'til it's over'.

  2000cited by this paper
• Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid.

  1999cited by this paper
• Novel Ras antagonist blocks human melanoma growth.

  1999cited by this paper
• Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice

  1999cited by this paper
• Concepts in Ras-directed therapy.

  1999cited by this paper
• K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors*

  1997cited by this paper
• Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I*

  1997cited by this paper
• Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth.

  1995cited by this paper
• Function and regulation of ras.

  1993cited by this paper
• Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.

  1993cited by this paper
• Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.

  1993cited by this paper
• Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies

  1992cited by this paper
• Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies

  1991cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• Noncompartmental Analysis Based on Statistical Moment Theory

  1982cited by this paper

• Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice

  2021cites this paper
• Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.

  2020cites this paper
• Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective

  2019cites this paper
• Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors.

  2019cites this paper
• An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors

  2018cites this paper
• Repositioning Salirasib as a new antimalarial agent.

  2018cites this paper
• Unravelling lung cancer heterogeneity and associated therapeutic responses using in vivo and ex vivo model systems

  2018cites this paper
• Chapter 17 – Brain Tumors

  2017cites this paper
• A potential non‐invasive glioblastoma treatment: Nose‐to‐brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles

  2017cites this paper
• Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.

  2017cites this paper
• Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.

  2017cites this paper
• Review Article A review of first-in-human small molecule oncology clinical trials

  2016cites this paper
• Targeted pulmonary delivery of inducers of host macrophage autophagy as a potential host-directed chemotherapy of tuberculosis.

  2016cites this paper
• A review of first-in-human small molecule oncology clinical trials

  2016cites this paper
• Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras‐Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation

  2015cites this paper
• KRAS mutant lung cancer: progress thus far on an elusive therapeutic target

  2015cites this paper
• Hybrid Molecule from Farnesylthiosalicylic Acid‐diamine and Phenylpropenoic Acid as Ras‐related Signaling Inhibitor with Potent Antitumor Activities

  2015cites this paper
• Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.

  2015cites this paper
• Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.

  2014cites this paper
• The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells

  2014cites this paper
• Prenylation of Aromatic Secondary Metabolites: A New Frontier for Development of Novel Drugs

  2014cites this paper
• Synthesis and biological evaluation of novel farnesylthiosalicylic acid/salicylic acid hybrids as potential anti-tumor agents

  2014cites this paper
• Identification of Gut Microbial Metabolites of a Synthetic Nitric Oxide-Releasing Farnesylthiosalicylic Acid Derivative, an Antitumor Agent

  2014cites this paper
• Synthesis and Biological Evaluation of Novel Farnesylthiosalicylic Acid Derivatives for Cancer Treatment

  2014cites this paper
• Targeting the RAS oncogene

  2013cites this paper
• Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms

  2013cites this paper
• Amide-modified prenylcysteine based Icmt inhibitors: Structure-activity relationships, kinetic analysis and cellular characterization.

  2012cites this paper
• S-Farnesyl-Thiopropionic Acid (FTPA) Triazoles as Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase.

  2012cites this paper
• Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer

  2012cites this paper
• Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007 – present)

  2012cites this paper
• Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.

  2012cites this paper
• Peptide Scaffolds: Flexible Molecular Structures With Diverse Therapeutic Potentials

  2012cites this paper
• ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways.

  2011cites this paper
• Role of Ras proteins in malignant peripheral nerve sheath tumors

  2011cites this paper
• Evaluation of Galectin-1 as a Target for Therapy in Neuroblastoma

  2011cites this paper
• A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

  2011cites this paper
• UTILIZING GENETICALLY ENGINEERED MOUSE MODELS OF PANCREATIC CANCER: EVALUATING THE ROLE OF CATHEPSIN B AND THE EFFICACY OF FARNESYL THIOSALICYLIC ACID

  2010cites this paper
• Prevention of Human Immunodeficiency Virus Type 1 Transmission by Pharmaceuticals Targeted to Host Proteins Required for Virus Infection? Consideration of Farnesyl Thiosalicylic Acid, a Ras Inhibitor

  2010cites this paper
• Farnesyltransferase inhibitors: where are we now?

  2010cites this paper
• Salirasib in the treatment of pancreatic cancer.

  2010influential citation
• Systems Biology of the MAPK1,2 Network

  2010cites this paper
• New druggable targets in the Ras pathway?

  2010cites this paper
• Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.

  2010cites this paper
• Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition

  2010cites this paper